Navigation Links
WaferGen to Present at the Cambridge Health Institute's Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
Date:3/19/2008

Chief Scientific Officer Dr. David Gelfand to Deliver Keynote Speech

FREMONT, Calif., March 19 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today announced that David Gelfand, Ph.D., chief scientific officer, will deliver a keynote speech at the Cambridge Healthtech Institute's Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference. The conference will be held March 26-28, 2008, at the Moscone North Convention Center in San Francisco, California.

Dr. Gelfand's speech, which will take place at 8:35 a.m. (PST) on Friday, March 28, will celebrate the 25th anniversary of polymerase chain reaction (PCR) and discuss the future of revolutionary technology. He is widely considered one of the world's foremost experts on PCR and DNA sequencing and is credited as the inventor of Thermus aquaticus (Taq) DNA Polymerase for use in PCR.

During his speech, Dr. Gelfand will highlight the key role that PCR has played in the success of the life science industry since its invention, particularly its contribution to the advent of the field of molecular diagnostics. He will also discuss the key advances in PCR over the past 25 years and outline future innovations that will be required for the realization of the technology's ultimate potential. Finally, Dr. Gelfand will provide an overview of WaferGen's SmartChip(TM) Real-Time PCR System, the world's first whole genome, high throughput gene expression real-time PCR platform.

About the SmartChip(TM) Real-Time PCR System

The SmartChip Real-Time PCR System(TM) is designed as the first whole genome, high throughput gene expression real-time PCR platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. It is estimated that the genetic analysis market alone (comprised of gene expression and genotyping analysis) had approximately $2.4 billion in worldwide revenues in 2006 ($1.74 billion for gene expression and $650 million for genotyping). Total global revenue for this market is estimated to reach approximately $5.0 billion by 2012.

WaferGen believes the SmartChip Real-Time PCR System will be the first whole genome, high throughput gene expression platform to combine the high-throughput capability and cost efficiencies of existing microarrays, with the sensitivity and accuracy of real-time PCR. Specifically, the SmartChip Real-Time PCR System's high density, rapid cycling configuration is expected to provide industry-leading throughput levels, while offering discovery and validation capabilities in a single step. The result will be the ability to conduct gene expression research at a fraction of the time and cost currently produced by existing instrument systems. For example, the company anticipates that whole genome assay time may be significantly reduced with the SmartChip Real-Time PCR System as compared to several days or months with microarrays or real-time PCR, respectively. This decrease in research time has broad economic implications across the drug development industry, particularly for pharmaceutical companies seeking avenues for reducing time to market for its therapeutics. Further, the company believes such throughput will dramatically impact the cost of such assays.

Beyond the significant time and cost advantages, the simplicity of the SmartChip Real-Time PCR System is unparalleled. The system will provide a number of key ease-of-use features including content-ready chips that can facilitate experiments without the need for advanced preparation of reagents. The user-friendly SmartChip Real-Time PCR System will accept samples out of the box, incorporating nearly all necessary substrates and chemicals. At the same time, the system will only require a very small sample size as compared to other technologies and platforms.

About WaferGen

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip(TM) is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide(TM), which was launched in 2006, represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research. Representative SmartSlide(TM) customers include Harvard University, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, Abbott Labs, and the National Institutes of Health (NIH).

To learn more about WaferGen, please visit the company's web site at http://www.wafergen.com.

Contact:

Vida Communication (on behalf of WaferGen)

Stephanie Diaz (investors) Tim Brons (media)

415-675-7400 415-675-7402

sdiaz@vidacommunication.com tbrons@vidacommunication.com


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
3. WaferGen Announces Management Team Promotions
4. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
5. Avicena Group to Present at Noble Financial Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CEL-SCI to Present at the Noble Financial Conference
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... New Orleans, La. (PRWEB) , ... March 23, ... ... of real-time, industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” ... for APMT customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s ...
(Date:3/22/2017)... -- Good Start Genetics, a leading family genomics company, ... covered lives mark through its most recent payor addition, ... . With newly signed contracts nationally and others in ... acceptance based on the quality of its science, the ... industry-leading customer care and support and its published cost-effectiveness ...
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT ... (the "Company" or "Propellon"), a start-up created by ... anti-cancer therapeutics. FACIT,s investment, combined with non-dilutive capital, ... program. The seed funding enables Propellon to accelerate ... the Company for financing and/or entering a strategic ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):